Cerebrospinal fluid corticotropin-releasing factor increases following haloperidol withdrawal in chronic schizophrenia

Steven D. Forman, Garth Bissette, Jeffrey Yao, Charles Nemeroff, Daniel P. van Kammen

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Corticotropin-releasing factor (CRF), an endogenous neuropeptide, has been shown to coordinate endocrine, behavioral and autonomic responses to stress. However, while previous studies of cerebrospinal fluid (CSF) CRF in schizophrenia have not demonstrated significant differences compared to control groups, these studies have not examined the effects of symptom severity or antipsychotic medication. CSF CRF concentrations increased in 18 of 21 male schizophrenic (DSM-III-R) patients after maintenance haloperidol was replaced by placebo (P<0.0001); there was also a trend for relatively greater increases in relapsers. CRF concentrations were not significantly related to severity of psychosis, depression, anxiety or negative symptoms. During haloperidol treatment, but not after medication withdrawal, worse childhood premorbid adjustment was associated with higher CSF CRF levels. Finally, in contrast to the positive correlation between CSF CRF and norepinephrine concentrations reported in depression, a negative trend was seen in this schizophrenic sample.

Original languageEnglish
Pages (from-to)43-51
Number of pages9
JournalSchizophrenia Research
Volume12
Issue number1
DOIs
StatePublished - Jan 1 1994
Externally publishedYes

Fingerprint

Corticotropin-Releasing Hormone
Haloperidol
Cerebrospinal Fluid
Schizophrenia
Depression
Social Adjustment
Neuropeptides
Diagnostic and Statistical Manual of Mental Disorders
Psychotic Disorders
Antipsychotic Agents
Norepinephrine
Anxiety
Placebos
Maintenance
Control Groups

Keywords

  • (Schizophrenia
  • ) Premorbid adjustment
  • Cerebrospinal fluid
  • Corticotropin-releasing factor
  • Haloperidol
  • Norepinephrine

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Behavioral Neuroscience
  • Biological Psychiatry
  • Neurology
  • Psychology(all)

Cite this

Cerebrospinal fluid corticotropin-releasing factor increases following haloperidol withdrawal in chronic schizophrenia. / Forman, Steven D.; Bissette, Garth; Yao, Jeffrey; Nemeroff, Charles; van Kammen, Daniel P.

In: Schizophrenia Research, Vol. 12, No. 1, 01.01.1994, p. 43-51.

Research output: Contribution to journalArticle

Forman, Steven D. ; Bissette, Garth ; Yao, Jeffrey ; Nemeroff, Charles ; van Kammen, Daniel P. / Cerebrospinal fluid corticotropin-releasing factor increases following haloperidol withdrawal in chronic schizophrenia. In: Schizophrenia Research. 1994 ; Vol. 12, No. 1. pp. 43-51.
@article{27ceaa3860d54a91959253a3f06be42e,
title = "Cerebrospinal fluid corticotropin-releasing factor increases following haloperidol withdrawal in chronic schizophrenia",
abstract = "Corticotropin-releasing factor (CRF), an endogenous neuropeptide, has been shown to coordinate endocrine, behavioral and autonomic responses to stress. However, while previous studies of cerebrospinal fluid (CSF) CRF in schizophrenia have not demonstrated significant differences compared to control groups, these studies have not examined the effects of symptom severity or antipsychotic medication. CSF CRF concentrations increased in 18 of 21 male schizophrenic (DSM-III-R) patients after maintenance haloperidol was replaced by placebo (P<0.0001); there was also a trend for relatively greater increases in relapsers. CRF concentrations were not significantly related to severity of psychosis, depression, anxiety or negative symptoms. During haloperidol treatment, but not after medication withdrawal, worse childhood premorbid adjustment was associated with higher CSF CRF levels. Finally, in contrast to the positive correlation between CSF CRF and norepinephrine concentrations reported in depression, a negative trend was seen in this schizophrenic sample.",
keywords = "(Schizophrenia, ) Premorbid adjustment, Cerebrospinal fluid, Corticotropin-releasing factor, Haloperidol, Norepinephrine",
author = "Forman, {Steven D.} and Garth Bissette and Jeffrey Yao and Charles Nemeroff and {van Kammen}, {Daniel P.}",
year = "1994",
month = "1",
day = "1",
doi = "10.1016/0920-9964(94)90083-3",
language = "English",
volume = "12",
pages = "43--51",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Cerebrospinal fluid corticotropin-releasing factor increases following haloperidol withdrawal in chronic schizophrenia

AU - Forman, Steven D.

AU - Bissette, Garth

AU - Yao, Jeffrey

AU - Nemeroff, Charles

AU - van Kammen, Daniel P.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - Corticotropin-releasing factor (CRF), an endogenous neuropeptide, has been shown to coordinate endocrine, behavioral and autonomic responses to stress. However, while previous studies of cerebrospinal fluid (CSF) CRF in schizophrenia have not demonstrated significant differences compared to control groups, these studies have not examined the effects of symptom severity or antipsychotic medication. CSF CRF concentrations increased in 18 of 21 male schizophrenic (DSM-III-R) patients after maintenance haloperidol was replaced by placebo (P<0.0001); there was also a trend for relatively greater increases in relapsers. CRF concentrations were not significantly related to severity of psychosis, depression, anxiety or negative symptoms. During haloperidol treatment, but not after medication withdrawal, worse childhood premorbid adjustment was associated with higher CSF CRF levels. Finally, in contrast to the positive correlation between CSF CRF and norepinephrine concentrations reported in depression, a negative trend was seen in this schizophrenic sample.

AB - Corticotropin-releasing factor (CRF), an endogenous neuropeptide, has been shown to coordinate endocrine, behavioral and autonomic responses to stress. However, while previous studies of cerebrospinal fluid (CSF) CRF in schizophrenia have not demonstrated significant differences compared to control groups, these studies have not examined the effects of symptom severity or antipsychotic medication. CSF CRF concentrations increased in 18 of 21 male schizophrenic (DSM-III-R) patients after maintenance haloperidol was replaced by placebo (P<0.0001); there was also a trend for relatively greater increases in relapsers. CRF concentrations were not significantly related to severity of psychosis, depression, anxiety or negative symptoms. During haloperidol treatment, but not after medication withdrawal, worse childhood premorbid adjustment was associated with higher CSF CRF levels. Finally, in contrast to the positive correlation between CSF CRF and norepinephrine concentrations reported in depression, a negative trend was seen in this schizophrenic sample.

KW - (Schizophrenia

KW - ) Premorbid adjustment

KW - Cerebrospinal fluid

KW - Corticotropin-releasing factor

KW - Haloperidol

KW - Norepinephrine

UR - http://www.scopus.com/inward/record.url?scp=0028269515&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028269515&partnerID=8YFLogxK

U2 - 10.1016/0920-9964(94)90083-3

DO - 10.1016/0920-9964(94)90083-3

M3 - Article

VL - 12

SP - 43

EP - 51

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

IS - 1

ER -